Document Detail


In vivo expression of angiotensin-(1-7) lowers blood pressure and improves baroreflex function in transgenic (mRen2)27 rats.
MedLine Citation:
PMID:  22526299     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Transgenic (mRen2)27 rats are hypertensive with impaired baroreflex sensitivity for control of heart rate compared with Hannover Sprague-Dawley rats. We assessed blood pressure and baroreflex function in male hemizygous (mRen2)27 rats (30-40 weeks of age) instrumented for arterial pressure recordings and receiving into the cisterna magna either an Ang-(1-7) fusion protein or a control fusion protein (CTL-FP). The maximum reduction in mean arterial pressure achieved was -38 ± 7 mm Hg on day 3, accompanied by a 55% enhancement in baroreflex sensitivity in Ang-(1-7) fusion protein-treated rats. Both the high-frequency alpha index (HF-α) and heart rate variability increased, suggesting increased parasympathetic tone for cardiac control. The mRNA levels of several components of the renin-angiotensin system in the dorsal medulla were markedly reduced including renin (-80%), neprilysin (-40%), and the AT1a receptor (-40%). However, there was a 2-fold to 3-fold increase in the mRNA levels of the phosphatases PTP-1b and dual-specificity phosphatase 1 in the medulla of Ang-(1-7) fusion protein-treated rats. Our finding that replacement of Ang-(1-7) in the brain of (mRen2)27 rats reverses in part the hypertension and baroreflex impairment is consistent with a functional deficit of Ang-(1-7) in this hypertensive strain. We conclude that the increased mRNA expression of phosphatases known to counteract the phosphoinositol 3 kinase and mitogen-activated protein kinases, and the reduction of renin and AT1a receptor mRNA levels may contribute to the reduction in arterial pressure and improvement in baroreflex sensitivity in response to Ang-(1-7).
Authors:
Maria A Garcia-Espinosa; Hossam A Shaltout; Patricia E Gallagher; Mark C Chappell; Debra I Diz
Related Documents :
24517779 - In situ measurement of electrical resistivity and seebeck coefficient simultaneously at...
6963329 - Effect of afterload on left ventricular performance in experimental animals. comparison...
22502629 - Pharmacists' awareness and attitude toward blood pressure measurement at home and in th...
17916009 - Assessment of longitudinal tissue doppler imaging of the left ventricular septum and fr...
22906919 - A single volar incision fasciotomy will decompress all three forearm compartments: a ca...
2530869 - Pharmacodynamics of amlodipine: hemodynamic effects and antianginal efficacy after atri...
8870799 - Lactic acid and amino acid fluctuations measured using microdialysis reflect physiologi...
3625859 - Compliance studies, pressure flow measurements and renal function assessment in patient...
23963129 - Synergistic deleterious effect of hypoxemia and hypovolemia on microcirculation in inte...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  60     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-15     Completed Date:  2012-12-26     Revised Date:  2013-08-14    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  150-7     Citation Subset:  IM    
Affiliation:
Radiation Oncology Department †Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1032, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin I / genetics,  metabolism*
Animals
Arterial Pressure* / genetics
Autonomic Nervous System / physiopathology
Baroreflex* / genetics
Brain / metabolism*,  physiopathology
Disease Models, Animal
Dual Specificity Phosphatase 1 / genetics,  metabolism
Gene Expression Regulation
Gene Transfer Techniques
Genetic Therapy*
Heart Rate
Hypertension / genetics,  metabolism,  physiopathology,  therapy*
Injections
Male
Mice
Neprilysin / genetics,  metabolism
Peptide Fragments / genetics,  metabolism*
Protein Tyrosine Phosphatase, Non-Receptor Type 1 / genetics,  metabolism
RNA, Messenger / metabolism
Rats
Rats, Transgenic
Receptor, Angiotensin, Type 1 / genetics,  metabolism
Renin / genetics,  metabolism*
Renin-Angiotensin System / genetics
Time Factors
Grant Support
ID/Acronym/Agency:
P01 HL051952/HL/NHLBI NIH HHS; R01 HL056973/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Agtr1a protein, rat; 0/Peptide Fragments; 0/RNA, Messenger; 0/Receptor, Angiotensin, Type 1; 0/Ren2 protein, mouse; 0/angiotensin I (1-7); 9041-90-1/Angiotensin I; EC 3.1.3.48/Dual Specificity Phosphatase 1; EC 3.1.3.48/Dusp1 protein, rat; EC 3.1.3.48/Protein Tyrosine Phosphatase, Non-Receptor Type 1; EC 3.1.3.48/Ptpn1 protein, rat; EC 3.4.23.15/Renin; EC 3.4.24.11/Neprilysin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Improving cardiac conduction with a skeletal muscle sodium channel by gene and cell therapy.
Next Document:  The posttranslocational chaperone lipoprotein PrsA is involved in both glycopeptide and oxacillin re...